Galera Therapeutics, Inc. (OTC:GRTX)
| Market Cap | $17.84M+328.8% |
| Revenue (ttm) | $0 |
| Net Income | $149.03M+1021.8% |
| EPS | $303.74+616.9% |
| Shares Out | 1.04M |
| PE Ratio | 0.06 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 420 |
| Open | $16.00 |
| Previous Close | $15.62 |
| Day's Range | $16.00 - $17.15 |
| 52-Week Range | $0.09 - $30.00 |
| Beta | 2.60 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | n/a |
About GRTX
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$GRTX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in GRTX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by GRTX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
GRTX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New GRTX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to GRTX from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from GRTX’s recent data — informational, not investment advice
